A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma

Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma

1991 • 5,657 citations

Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth

1997 • 4,504 citations

Cancer statistics, 2000

2000 • 3,907 citations

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

1994 • 3,367 citations

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

1999 • 2,565 citations

Thalidomide is an inhibitor of angiogenesis.

1994 • 2,460 citations

Clinical Applications of Research on Angiogenesis

1995 • 2,300 citations

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

1997 • 1,705 citations

Angiostatin induces and sustains dormancy of human primary tumors in mice

1996 • 1,193 citations

COX-2 inhibitors

1999 • 1,177 citations

THALIDOMIDE AND CONGENITAL ABNORMALITIES

1961 • 1,089 citations

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.

1993 • 1,058 citations

Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation

1996 • 752 citations

Regulation of angiogenesis via vascular endothelial growth factor receptors.

2000 • 749 citations

Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.

1999 • 660 citations

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

1997 • 657 citations

Bone marrow angiogenesis and progression in multiple myeloma

1994 • 656 citations

Bone Marrow Neovascularization, Plasma Cell Angiogenic Potential, and Matrix Metalloproteinase-2 Secretion Parallel Progression of Human Multiple Myeloma

1999 • 590 citations

Thalidomide Costimulates Primary Human T Lymphocytes, Preferentially Inducing Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8+ Subset

1998 • 576 citations

Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma

2000 • 547 citations

Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia.

1997 • 546 citations

Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies.

1999 • 543 citations

VEGFs, receptors and angiogenesis

1999 • 523 citations

Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity

1999 • 490 citations

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials

1998 • 486 citations

Vascular Endothelial Growth Factor, a Possible Paracrine Growth Factor in Human Acute Myeloid Leukemia

1997 • 465 citations

Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count, and computer image analysis

1995 • 450 citations

Effects of Thalidomide and Related Metabolites in a Mouse Corneal Model of Neovascularization

1997 • 447 citations

Thalidomide in the Treatment of the Mucocutaneous Lesions of the Behcet Syndrome

1998 • 445 citations

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.

1998 • 429 citations

Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade Gliomas

2000 • 428 citations

Thalidomide for the Treatment of Oral Aphthous Ulcers in Patients with Human Immunodeficiency Virus Infection

1997 • 423 citations

The Treatment of Multiple Myeloma

1994 • 409 citations

Multiple Myeloma

1997 • 389 citations

Maintenance Treatment with Recombinant Interferon Alfa-2b in Patients with Multiple Myeloma Responding to Conventional Induction Chemotherapy

1990 • 389 citations

“Benign” Monoclonal Gammopathy—After 20 to 35 Years of Follow-Up

1993 • 343 citations

Prognostic value of bone marrow angiogenesis in multiple myeloma.

2000 • 321 citations

Medicine and the Law

1966 • 308 citations

Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy.

1998 • 307 citations

Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade

1996 • 295 citations

Inhibition of Angiogenesis by Thalidomide Requires Metabolic Activation, Which Is Species-dependent

1998 • 293 citations

Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis?

1998 • 279 citations

The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures

1995 • 266 citations

Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial

1996 • 199 citations

Preclinical Safety Evaluation of rhuMAbVEGF, an Antiangiogenic Humanized Monoclonal Antibody

1999 • 198 citations

Thalidomide as salvage therapy for chronic graft-versus-host disease

1995 • 194 citations

COMMENTARY Tumour angiogenesis and prognosis

1997 • 187 citations

Neoplastic Diseases of the Blood

2012 • 181 citations

Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies

1996 • 168 citations

Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma

1999 • 156 citations

COX‐2 Inhibitors: A New Class of Antiangiogenic Agents

1999 • 155 citations

WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients.

1971 • 149 citations

Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.

1994 • 139 citations

Therapy with thalidomide in refractory multiple myeloma patients — the revival of an old drug

2000 • 136 citations

Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production.

1996 • 117 citations

TUMOUR ANGIOGENESIS

1996 • 115 citations

The pathogenesis of chronic immune (idiopathic) thrombocytopenic purpura

2000 • 113 citations

Myeloma : biology and management

1995 • 104 citations

Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.

1995 • 102 citations

Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma

1997 • 100 citations

Interferon alfa‐2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study

1995 • 96 citations

Thalidomide in the Treatment of the Mucocutaneous Lesions of the Behcet Syndrome

1998 • 94 citations

Interferon-alpha for induction and maintenance in multiple myeloma: Results of two multicenter randomized trials and summary of other studies

1995 • 90 citations

Neoplastic Diseases of the Blood

1996 • 85 citations

The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities.

1998 • 84 citations

Expression of vascular permeability factor (VPFNEGF) messenger RNA by plasma cells: Possible involvement in the development of edema in chronic inflammation

1995 • 76 citations

A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group

1995 • 75 citations

The effect of thalidomide on experimental tumors and metastases

1996 • 75 citations

Biology and management

1995 • 73 citations

Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy

1997 • 71 citations

Syndecan-1 Expression on Malignant Cells from the Blood and Marrow of Patients with Plasma Cell Proliferative Disorders and B-Cell Chronic Lymphocytic Leukemia

1998 • 70 citations

The role of autologous hematopoietic stem cell transplantation in multiple myeloma.

1997 • 66 citations

Clinical trials of antiangiogenic agents

1997 • 65 citations

The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma

1999 • 55 citations

Therapeutic potentials of angiostatin in the treatment of cancer.

1999 • 53 citations

Antiangiogenic agents

1999 • 49 citations

Pharmacology of thalidomide

2000 • 46 citations

Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs.

1998 • 40 citations

Biology and therapy of multiple myeloma in 1996.

1997 • 33 citations

Was tumour necrosis factor-α responsible for the fetal malformations associated with thalidomide in the early 1960s?

1998 • 27 citations

Intensive treatment strategies in multiple myeloma.

1997 • 24 citations

Interferon in the Treatment of Multiple Myeloma

1998 • 20 citations

Endostatin: A Promising Drug for Antiangiogenic Therapy

1999 • 17 citations

Refractory and Relapsing Multiple Myeloma Treated by Blood Stem Cell Transplantation

1995 • 17 citations

The human basic fibroblast growth factor gene (FGFB) is assigned to chromosome 4q25

1990 • 16 citations

Thalidomide frequently induces good partial remission and best response ever in patients with advanced myeloma and prior high dose melphalan and autotransplant.

1999 • 10 citations

Thalidomide is very effective for chronic GVHD but has no activity in acute GVHD.

1997 • 2 citations